9 results match your criteria: "centre National de référence des maladies autoinflammatoires et de l'amylose[Affiliation]"
Article Synopsis
- The three main types of systemic amyloidosis are transthyretin amyloidosis (ATTR), immunoglobulin amyloidosis (AL), and inflammatory amyloidosis (AA), each with distinct characteristics and causes.
- ATTR has two forms: wild type, common in heart disease, and a rare genetic variant linked to peripheral neuropathy; advancements in treatment have focused on stabilizing transthyretin.
- AL is a hematological condition causing toxicity from abnormal immunoglobulin light chains, mainly affecting the heart and kidneys, while AA is associated with chronic inflammatory diseases but is less common due to effective treatments.
Cryoglobulinemia - One Name for Two Diseases.
N Engl J Med
October 2024
From Sorbonne Universités, Centre National de Références des Maladies Autoimmunes Systémiques Rares, Centre National de Références des Maladies Autoinflammatoires et de l'Amylose Inflammatoire, the Department of Inflammation, Immunopathology, and Biotherapy, Clinical Investigation Center in Biotherapy, INSERM 959, and Département de Médecine Interne et Immunologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris - all in Paris.
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study.
RMD Open
June 2023
AP-HP, Hôpital Pitié Salpetrière, Department of Internal Medicine and Clinical Immunology France, Centre national de référence maladies Autoimmunes Systémiques rares, Centre national de référence maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Universités, Paris, France.
Article Synopsis
- A study compared two ways of giving a medicine called tocilizumab to patients with a disease called Takayasu arteritis (TAK).
- They looked at 109 patients from different countries and found that both methods worked similarly well after 6 months, with about 69% showing improvement.
- However, patients who got tocilizumab as a shot under the skin had a higher chance of getting worse again compared to those who received it through an IV.
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients.
Rheumatology (Oxford)
April 2022
Sorbonne Université, AP-HP, Hôpital Pitié Salpetrière, Department of Internal Medicine and Clinical Immunology France, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Centre National de Référence Maladies Autoinflammatoires et Amylose, and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Paris, France.
Article Synopsis
- This study evaluates the safety and effectiveness of TNF-α antagonists and tocilizumab in treating Takayasu arteritis (TAK) in 209 patients, primarily young women.
- Results show that both treatment options achieved a high rate of complete response (66% for TNF-α and 70% for tocilizumab) after 6 months, although older age was positively correlated with response while certain baseline symptoms were negatively associated.
- The incidence of treatment relapses and adverse effects was similar for both therapies, indicating that they are equally effective for managing refractory TAK over a median follow-up of 36 months.
Women and Pregnancy in Thromboangiitis Obliterans.
J Vasc Res
December 2021
Department of Internal Medicine and Clinical Immunology, Centre National de Référence des Maladies Autoimmunes Systémiques Rares, Centre National de Référence des Maladies Autoinflammatoires et de l'Amylose, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Universités, INSERM, UMR_S 959, Paris, France.
Data regarding women and thromboangiitis obliterans (TAO) are conflicted, and a few cases of pregnancy have been described. We aimed to describe the interplay between TAO and pregnancies. Among 224 TAO patients, 22.
View Article and Find Full Text PDFExpert opinion on the use of biological therapy in non-infectious uveitis.
Expert Opin Biol Ther
May 2019
r Inflammation-Immunopathology-Biotherapy Department (DHU i2B) , Sorbonne Universités, UPMC Univ Paris 06, UMR 7211 , Paris , France.
Introduction: Conventional immunosuppressive drugs, anti-TNF alpha treatments and biotherapies are increasingly being used in non-infectious uveitis.
Areas Covered: The present work was led by a multidisciplinary panel of experts, including internal medicine specialists, rheumatologists and ophthalmologists, and proposes an extensive review on the use of biological agents in non-infectious uveitis.
Expert Opinion: In case of dependency to steroids or sight-threatening disease, conventional immunosuppressive drugs (methotrexate, azathioprine and mycophenolate mofetil) and/or biological therapies such as anti-TNF alpha treatments (adalimumab, infliximab) can be used to achieve and maintain disease quiescence.
Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients.
J Am Heart Assoc
December 2018
1 UPMC Univ Paris 06 UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B) Sorbonne Universités Paris France.
Background Data regarding long-term outcome of patients with thromboangiitis obliterans are lacking and most series come from India and Japan. In this study, we assess long-term outcome and prognostic factors in a large cohort of thromboangiitis obliterans. Methods and Results Retrospective multicenter study of characteristics and outcomes of 224 thromboangiitis obliterans patients fulfilling Papa's criteria were analyzed.
View Article and Find Full Text PDF[Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel].
Rev Med Interne
September 2018
Inflammation-immunopathology-biotherapy department (DHU i2B), Sorbonne universités, UPMC université Paris 06, UMR 7211, 75005 Paris, France; Inserm, UMR_S 959, 75013 Paris, France; CNRS, FRE3632, 75005 Paris, France; Department of internal medicine and clinical immunology, groupe hospitalier Pitié-Salpêtrière, AP-HP, 75013 Paris, France; Centre national de référence des maladies autoimmunes systémiques rares, centre National de référence des maladies autoinflammatoires et de l'amylose, France. Electronic address:
Conventional immunosuppressive drugs, anti-TNF alpha and other biotherapies used in clinical practice are capable of controlling non-infectious anterior uveitis, posterior uveitis and panuveitis. The present work has been led by a multidisciplinary panel of experts, internists, rheumatologists and ophthalmologists and is based on a review of the literature. In case of corticodependency or sight-threatening disease, conventional immunosuppressive drugs (methotrexate, azathioprine and mycophenolate mofetil) and/or anti-TNF alpha (adalimumab, infliximab) are used to achieve and maintain remission.
View Article and Find Full Text PDF[Uveitis: From diagnosis to treatment].
Rev Med Interne
September 2018
Service de médecine interne, hôpital de la Croix-Rousse, hospices Civils-de-Lyon, 103, grande rue de la Croix-Rousse, 69317 Lyon cedex 04, France; Faculté de médecine Lyon-Sud, université Claude-Bernard-Lyon 1, Lyon, France. Electronic address: